SRPT catalyst calendar

Sarepta Therapeutics, Inc.

Upcoming catalysts
10
Cash runway
11.7 months
Cash & investments
$788M
Phase 3 programs
8

Sarepta Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) on October 31, 2026. There are 10 upcoming events on record.

Cash runway is approximately 11.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 39 concluded trials, 59% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 31, 2026 A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) Trial Milestone Phase 3
December 23, 2026 est. Next quarterly earnings (projected) Earnings —
December 31, 2026 Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy Trial Milestone Phase 1/Phase 2
May 31, 2027 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) Trial Milestone Phase 3
August 31, 2027 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting Trial Milestone Phase 4
November 30, 2027 A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease Trial Milestone Phase 1
December 31, 2027 A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort Trial Milestone Phase 1
August 28, 2028 A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) Trial Milestone Phase 1
December 31, 2028 Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 Trial Milestone Phase 1/Phase 2
October 31, 2033 A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study Trial Milestone Phase 3

Track SRPT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open SRPT in the tracker

Recent history

DateEventTypePhase
September 23, 2026 8-K filed: Material agreement Corporate —
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 27, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
June 4, 2026 8-K filed: Leadership change Corporate —
May 6, 2026 Quarterly results filed (8-K) Earnings —
February 25, 2026 Quarterly results filed (8-K) Earnings —
February 25, 2026 8-K filed: Leadership change Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 19, 2025 8-K filed: Material agreement Corporate —
December 11, 2025 8-K filed: Other event Filing —
December 8, 2025 8-K filed: Leadership change Corporate —
November 3, 2025 Quarterly results filed (8-K) Earnings —
October 10, 2025 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) Trial Milestone Phase 1
August 29, 2025 8-K filed: Material agreement, Other event Corporate —
August 13, 2025 8-K filed: Leadership change Corporate —
August 5, 2025 A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74 Trial Milestone Phase 1
July 21, 2025 8-K filed: Other event Filing —
July 16, 2025 Quarterly results filed (8-K) Earnings —
June 18, 2025 Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States Trial Milestone Phase 1
June 13, 2025 A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) Trial Milestone Phase 1
June 6, 2025 8-K filed: Leadership change Corporate —
March 4, 2025 A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 Trial Milestone Phase 3
January 14, 2025 Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) Trial Milestone Phase 1/Phase 2
November 12, 2024 Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) Trial Milestone Phase 3
October 30, 2023 Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment Trial Milestone Phase 2
October 4, 2023 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) Trial Milestone Phase 3
July 26, 2023 An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy Trial Milestone Phase 3
April 25, 2023 A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) Trial Milestone Phase 1/Phase 2
August 31, 2022 A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995) Trial Milestone Phase 2
August 25, 2021 An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.